



FIGURE 1

1 2 3 4 5 6 7 8



β -actin

FIGURE 2



IL-10----

FIGURE 4




FIGURE 5A

1 2 3 4 5



FIGURE 5B

1 2 3 4 5




FIGURE 6




FIGURE 7

	Leader -----	
RAT	ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T-----G-----	67
HUM	-----GA-----TG-----C-----CT-----T-----G-T-----T-----G-----	55
	 V-like domain -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----	189
RAT	AAAGCCGTAGGCCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTGAGCCACCT	268
MOU	-----GA-----C-----A-----A-C-----TG-----	268
HUM	-----T-----A-----C-T-----G-GAA-----G-G-C-----TG-----	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG-----A-----G-----T-----CA-----	335
HUM	-T-G-----A-----T-CC-----C-A--T--C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA-----GA-C-----C-----T-----CA-----A-A-----	402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G	390
	 C-like domain -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C-CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTCAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG--T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	---A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--	591
RAT	AAAGACCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC--	658
	 Transmembrane region -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCCTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T-----A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--	725
	 Cytoplasmic region -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCAGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C--C-A-----A-----C-G-----T-----G-----C-A--	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	--A-----	837
HUM	----TG-----AG-T-----A-----C-----	825

FIGURE 8

Leader sequence-----

-30 -1

RAT M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A

MOU -----L-----I-----G-----

HUM - I - M - - S - - - V - - V M - - - V - - C - -

|V-like domain (domain I) ----- *

RAT Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L

MOU -----A-----S-----

HUM ---Q-----E---Y-----K-----QNA---A--

31 **

RAT I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y

MOU -----S-----T-----A--

HUM -----E N-----

61 ** **

RAT K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M

MOU -----V-----W--S-----H I G-----

HUM ---K-----Q-----Q---T-----I---E-----

91* ** |C-like domain (domain II)-----

RAT C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N

MOU -----T-----Q-----

HUM -----F G---I-----V-----S-----K

121 ** .

RAT Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E

MOU -----T-----T-----

HUM F S-----M V F-----V P R-----

151**

RAT N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K

MOU -----F-----

HUM ---V T L S--P-----H I-----N-----

181 . |Transmembrane region -----

RAT E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L

MOU -----

HUM -----H---T--T--F---T V N---Y-----

211 |Cytoplasmic region -----

RAT L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S

MOU -----I-----

HUM -----V-----D-----L

241

RAT S Q G M Q R M K

MOU -----

HUM -----V--K---T

* invariant cysteine residues, ** invariant asparagine (N-linked oligosaccharides)

FIGURE 10





FIGURE 11



NPC from Flt3 treated mice

FIGURE 12






FIGURE 13



CELLS added to C3H RESPONDER SPLEEN CELLS

FIGURE 14



NPC cells infused into renal transplant recipients

FIGURE 15




FIGURE 16





FIGURE 17



Monoclonal antibodies added to culture

FIGURE 18A





FIGURE 18B





[illegible]

FIGURE 19




FIGURE 20

Role of CD4⁺/CD8⁺ cells in tumor immunity in bone marrow transplant recipients




FIGURE 21

CD200Fc reverses tumor protection in C3H recipients of C57BL/6 bone marrow




FIGURE 22

CD200Fc reverses protection from early mortality in C57BL/6 mice immunized with CD80-transfected EL4 cells




FIGURE 23

Anti-CD200 reveals protection in mice preimmunized with CD86-tumor cells






FIGURE 24

**Relative CD200 mRNA expression in spleen following
immunization with EL4-CD86 vs EL4-CD80**



Cells used for immunization of C57BL/6

FIGURE 25

0000034460





FIGURE 26

CD200Fc interacts with anti-CD4/CD8 to block tumor immunity

a)



b)




FIGURE 27

CD200Fc reverses protection from early mortality in anti-CD4 treated C57BL/6 mice immunized with CD80-transfected EL4 cells





FIGURE 28


FIGURE 29A and B



A

B

FIGURE 30A and B



A

B

FIGURE 31A and B

